Video

Dr. Davis on the Influence of Racial Constructs and Genetic Ancestry in TNBC

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.

Melissa B. Davis, PhD, assistant professor, Cell and Developmental Biology, Department of Surgery, scientific director, International Center for the Study of Breast Cancer Subtypes, Weill Cornell Medical College, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer (TNBC).

Worse outcomes in patients with TNBC have been associated with social constructs, Davis says. However, these are not the only factors that can contribute to outcomes for these patients. Genetic lineage can also correlate with social constructs to contribute to outcomes, Davis adds. For example, in African American patients, West African ancestry is associated with TNBC subtypes, Davis explains.

When comparing genetic ancestry vs race, it was found that genetic pathways for comorbidities, such as diabetes, inflammation, and metabolic disorders, were imprinted on the tumor cells in patients in the race group, Davis continues. These findings help create the link between factors that are genetically driven from ancestry and genetically driven because of a lived experience, Davis concludes.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD